R&D Heads At GSK & AZ Say Key To Success Lies In Smart Risk Taking

AZ's Mene Pangalos and GSK's Hal Barron are at different stages of overseeing culture changes in their respective R&D workforces - but both agreed at a recent conference that such transformations are key for the future viability of their drug companies.

SWOT
Pair Say R&D needs better decision-making and focused risk-taking • Source: Shutterstock

The raison d'être of any R&D chief is finding a way to increase the successful translation of innovation into a rejuvenated pipeline and successful new drug launches. The R&D heads of Britain's two biggest pharma companies were asked at a recent London conference what they believe the secret in doing that is – and both agreed that in large part it lies in creating a smarter, more focused risk-taking culture within their teams.

AstraZeneca PLC's Mene Pangalos and GlaxoSmithKline PLC's Hal Barron were featured speakers at this year's FT Global Pharmaceutical...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.